[
  {
    "title": "普利制药(300630.SZ)：注射用达托霉素获得中国药品注册批件",
    "href": "http://stock.jrj.com.cn/2023/01/05161037261347.shtml",
    "datetime": "2023-01-05 16:10:10",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用更昔洛韦在斯里兰卡获批上市",
    "href": "http://stock.jrj.com.cn/2022/12/28164537243373.shtml",
    "datetime": "2022-12-28 16:45:49",
    "code": "300630"
  },
  {
    "title": "普利制药：盐酸多巴酚丁胺注射液获美国FDA批准通知",
    "href": "http://stock.jrj.com.cn/2022/12/27160737240536.shtml",
    "datetime": "2022-12-27 16:07:48",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：盐酸多巴酚丁胺注射液获美FDA批准通知",
    "href": "http://stock.jrj.com.cn/2022/12/27160437240549.shtml",
    "datetime": "2022-12-27 16:04:35",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：林可霉素注射液获美FDA批准通知",
    "href": "http://stock.jrj.com.cn/2022/12/26180637238657.shtml",
    "datetime": "2022-12-26 18:06:33",
    "code": "300630"
  },
  {
    "title": "普利制药：公司生产退热、止痛、感冒等类的药品",
    "href": "http://stock.jrj.com.cn/2022/12/21140437228049.shtml",
    "datetime": "2022-12-21 14:04:46",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：控股股东之一致行动人朱小平质押2168万股",
    "href": "http://stock.jrj.com.cn/2022/12/09195037202724.shtml",
    "datetime": "2022-12-09 19:50:06",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用更昔洛韦获得奥地利联邦卫生安全办公室上市许可",
    "href": "http://stock.jrj.com.cn/2022/12/04164537186928.shtml",
    "datetime": "2022-12-04 16:45:36",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：预计将触发可转债转股价向下修正的条件",
    "href": "http://stock.jrj.com.cn/2022/12/02214437185995.shtml",
    "datetime": "2022-12-02 21:44:46",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用盐酸万古霉素获乌克兰卫生部上市许可",
    "href": "http://stock.jrj.com.cn/2022/11/30165137178454.shtml",
    "datetime": "2022-11-30 16:51:05",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：第二期员工持股计划锁定期届满 涉及59.5万股",
    "href": "http://stock.jrj.com.cn/2022/11/22171637157845.shtml",
    "datetime": "2022-11-22 17:16:14",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：格隆溴铵原料药获得CEP证书",
    "href": "http://stock.jrj.com.cn/2022/11/22171337157849.shtml",
    "datetime": "2022-11-22 17:13:36",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用更昔洛韦获得芬兰国家药物署上市许可",
    "href": "http://stock.jrj.com.cn/2022/11/20164837152443.shtml",
    "datetime": "2022-11-20 16:48:09",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用盐酸万古霉素获得加拿大卫生部上市许可",
    "href": "http://stock.jrj.com.cn/2022/11/16182837144327.shtml",
    "datetime": "2022-11-16 18:28:31",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用盐酸万古霉素获得加拿大卫生部上市许可",
    "href": "http://stock.jrj.com.cn/2022/11/16182537144316.shtml",
    "datetime": "2022-11-16 18:25:22",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用艾司奥美拉唑钠获德国上市许可",
    "href": "http://stock.jrj.com.cn/2022/11/09170737124397.shtml",
    "datetime": "2022-11-09 17:07:19",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)子公司获得药品GMP符合性检查结果通知书",
    "href": "http://stock.jrj.com.cn/2022/11/06171037115300.shtml",
    "datetime": "2022-11-06 17:10:17",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)第三季度净利润1.68亿元、同比增长1.70%",
    "href": "http://stock.jrj.com.cn/2022/10/24194437079197.shtml",
    "datetime": "2022-10-24 19:44:33",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：子公司奥卡西平片获德国上市许可",
    "href": "http://stock.jrj.com.cn/2022/10/20170437070377.shtml",
    "datetime": "2022-10-20 17:04:08",
    "code": "300630"
  },
  {
    "title": "普利制药“注射用更昔洛韦”通过瑞典药品署技术审评：有望在瑞典丹麦芬兰挪威和奥地利上市销售",
    "href": "http://stock.jrj.com.cn/2022/10/20093237068938.shtml",
    "datetime": "2022-10-20 09:32:32",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用更昔洛韦通过瑞典药品署技术审评",
    "href": "http://stock.jrj.com.cn/2022/10/19165237067261.shtml",
    "datetime": "2022-10-19 16:52:57",
    "code": "300630"
  },
  {
    "title": "普利制药：硝普钠注射液获得澳大利亚药物管理局上市许可",
    "href": "http://stock.jrj.com.cn/2022/10/13172537053198.shtml",
    "datetime": "2022-10-13 17:25:20",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：硝普钠注射液获得澳大利亚药物管理局上市许可",
    "href": "http://stock.jrj.com.cn/2022/10/13172337053217.shtml",
    "datetime": "2022-10-13 17:23:36",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用艾司奥美拉唑钠获中国药品注册批件",
    "href": "http://stock.jrj.com.cn/2022/10/10181537044589.shtml",
    "datetime": "2022-10-10 18:15:15",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用阿奇霉素获新加坡HSA上市许可",
    "href": "http://stock.jrj.com.cn/2022/09/26183637022439.shtml",
    "datetime": "2022-09-26 18:36:29",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：与谷森医药签订GS-00202片剂委托生产战略合作框架协议",
    "href": "http://stock.jrj.com.cn/2022/09/13160736991253.shtml",
    "datetime": "2022-09-13 16:07:02",
    "code": "300630"
  },
  {
    "title": "普利制药：子公司与谷森医药签订委托生产战略合作框架协议",
    "href": "http://stock.jrj.com.cn/2022/09/13154936991204.shtml",
    "datetime": "2022-09-13 15:49:55",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用泮托拉唑钠获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2022/09/04172236972013.shtml",
    "datetime": "2022-09-04 17:22:41",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：特利加压素注射液获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2022/09/04171936972004.shtml",
    "datetime": "2022-09-04 17:19:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：美索巴莫注射液获美FDA批准上市",
    "href": "http://stock.jrj.com.cn/2022/08/31160936958159.shtml",
    "datetime": "2022-08-31 16:09:42",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)上半年净利2.88亿元，同比增长27.75%",
    "href": "http://stock.jrj.com.cn/2022/08/29234336949846.shtml",
    "datetime": "2022-08-29 23:43:19",
    "code": "300630"
  },
  {
    "title": "普利制药：硝普钠氯化钠注射液获得FDA上市批准",
    "href": "http://stock.jrj.com.cn/2022/08/28201936944682.shtml",
    "datetime": "2022-08-28 20:19:34",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：硝普钠氯化钠注射液在美获批上市",
    "href": "http://stock.jrj.com.cn/2022/08/28185536944589.shtml",
    "datetime": "2022-08-28 18:55:44",
    "code": "300630"
  },
  {
    "title": "A股异动 | 普利制药涨4% 注射用泮托拉唑钠获新西兰药品管理局上市许可",
    "href": "http://stock.jrj.com.cn/2022/08/08131836878431.shtml",
    "datetime": "2022-08-08 13:18:28",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)注射用泮托拉唑钠获得新西兰药品管理局上市许可",
    "href": "http://stock.jrj.com.cn/2022/08/07164336876156.shtml",
    "datetime": "2022-08-07 16:43:09",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：已累计回购180.6023万股",
    "href": "http://stock.jrj.com.cn/2022/08/02174736863425.shtml",
    "datetime": "2022-08-02 17:47:06",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：子公司氢氧化镁原料药获得CEP证书",
    "href": "http://stock.jrj.com.cn/2022/07/28170836850763.shtml",
    "datetime": "2022-07-28 17:08:08",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：子公司环磷酰胺原料药收到FDA接收通知函",
    "href": "http://stock.jrj.com.cn/2022/07/27171036847330.shtml",
    "datetime": "2022-07-27 17:10:57",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：依替巴肽注射液拟中选第七批国采",
    "href": "http://stock.jrj.com.cn/2022/07/13201836808701.shtml",
    "datetime": "2022-07-13 20:18:12",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：2021年年度权益分派10派1.918元 股权登记日7月12日",
    "href": "http://stock.jrj.com.cn/2022/07/05202136784785.shtml",
    "datetime": "2022-07-05 20:21:16",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：年产治疗天花药物1吨布林西多福韦和1吨特考韦瑞原料药建设项目取得项目备案",
    "href": "http://stock.jrj.com.cn/2022/07/04152236779779.shtml",
    "datetime": "2022-07-04 15:22:33",
    "code": "300630"
  },
  {
    "title": "A股异动 | 普利制药涨5% 考韦瑞项目取得备案",
    "href": "http://stock.jrj.com.cn/2022/07/04141336779572.shtml",
    "datetime": "2022-07-04 14:13:38",
    "code": "300630"
  },
  {
    "title": "普利制药：特考韦瑞项目取得备案",
    "href": "http://stock.jrj.com.cn/2022/07/03180336777772.shtml",
    "datetime": "2022-07-03 18:03:44",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)截至6月底已累计回购180.6023万股",
    "href": "http://stock.jrj.com.cn/2022/07/01180736775952.shtml",
    "datetime": "2022-07-01 18:07:24",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用兰索拉唑通过仿制药质量和疗效一致性评价",
    "href": "http://stock.jrj.com.cn/2022/06/26164536759234.shtml",
    "datetime": "2022-06-26 16:45:23",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：子公司钆特酸葡胺原料药收到FDA接收通知函",
    "href": "http://stock.jrj.com.cn/2022/06/20162236743015.shtml",
    "datetime": "2022-06-20 16:22:32",
    "code": "300630"
  },
  {
    "title": "普利制药：钆特酸葡胺原料药收到FDA接收通知函",
    "href": "http://stock.jrj.com.cn/2022/06/20162136742981.shtml",
    "datetime": "2022-06-20 16:21:49",
    "code": "300630"
  },
  {
    "title": "普利制药拟投资500万通过全资子公司安徽普利药业有限公司设立全资孙公司",
    "href": "http://stock.jrj.com.cn/2022/06/07205236710415.shtml",
    "datetime": "2022-06-07 20:52:11",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：拟新设全资孙公司安徽普瑞 注册资本500万",
    "href": "http://stock.jrj.com.cn/2022/06/07173536709612.shtml",
    "datetime": "2022-06-07 17:35:56",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：截至5月底已累计回购146.12万股",
    "href": "http://stock.jrj.com.cn/2022/06/01194536698065.shtml",
    "datetime": "2022-06-01 19:45:16",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用伏立康唑获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2022/05/29175236687408.shtml",
    "datetime": "2022-05-29 17:52:52",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：左乙拉西坦注射液在阿联酋获批上市",
    "href": "http://stock.jrj.com.cn/2022/05/19164836662489.shtml",
    "datetime": "2022-05-19 16:48:56",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：不向下修正“普利转债”的转股价",
    "href": "http://stock.jrj.com.cn/2022/05/18221036660403.shtml",
    "datetime": "2022-05-18 22:10:21",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：左乙拉西坦注射液获得加拿大批准通知",
    "href": "http://stock.jrj.com.cn/2022/05/18194136659896.shtml",
    "datetime": "2022-05-18 19:41:19",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：截至4月底已累计回购31.86万股",
    "href": "http://stock.jrj.com.cn/2022/05/05173736570744.shtml",
    "datetime": "2022-05-05 17:37:45",
    "code": "300630"
  },
  {
    "title": "普利制药2022年第一季度净利1.62亿同比增长33.44% 一季度经营规模上涨",
    "href": "http://stock.jrj.com.cn/2022/05/03185036546072.shtml",
    "datetime": "2022-05-03 18:50:46",
    "code": "300630"
  },
  {
    "title": "普利制药2021年净利4.17亿同比增长2.25% 董事长范敏华薪酬67.42万",
    "href": "http://stock.jrj.com.cn/2022/04/27111036482493.shtml",
    "datetime": "2022-04-27 11:10:06",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：一季度净利升33.44%至1.62亿元",
    "href": "http://stock.jrj.com.cn/2022/04/26143836474941.shtml",
    "datetime": "2022-04-26 14:38:24",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)2021年度净利升2.25%至4.17亿元 拟10派1.91元",
    "href": "http://stock.jrj.com.cn/2022/04/26143536474944.shtml",
    "datetime": "2022-04-26 14:35:37",
    "code": "300630"
  },
  {
    "title": "A股异动 | 普利制药(300630.SZ)涨6% 绩后获券商看好",
    "href": "http://stock.jrj.com.cn/2022/04/26135536474808.shtml",
    "datetime": "2022-04-26 13:55:41",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用更昔洛韦获哥斯达黎加卫生部上市许可",
    "href": "http://stock.jrj.com.cn/2022/04/19193336401468.shtml",
    "datetime": "2022-04-19 19:33:08",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：硝普钠注射液获批上市",
    "href": "http://stock.jrj.com.cn/2022/04/17170836368815.shtml",
    "datetime": "2022-04-17 17:08:46",
    "code": "300630"
  },
  {
    "title": "【龙虎榜】普利制药4月15日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/04/15180036345553.shtml",
    "datetime": "2022-04-15 18:00:11",
    "code": "300630"
  },
  {
    "title": "年报季报业绩双增长 普利制药股价“离奇”大跌",
    "href": "http://stock.jrj.com.cn/2022/04/15082336341209.shtml",
    "datetime": "2022-04-15 08:23:57",
    "code": "300630"
  },
  {
    "title": "【龙虎榜】普利制药4月14日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/04/14180036335996.shtml",
    "datetime": "2022-04-14 18:00:06",
    "code": "300630"
  },
  {
    "title": "普利制药放量大跌19.31% 四机构合计卖出2.88亿元",
    "href": "http://stock.jrj.com.cn/2022/04/14164436335339.shtml",
    "datetime": "2022-04-14 16:44:05",
    "code": "300630"
  },
  {
    "title": "普利制药2021年净利4.11亿同比增长0.84% 发展各项产品推广",
    "href": "http://stock.jrj.com.cn/2022/04/14051236329697.shtml",
    "datetime": "2022-04-14 05:12:24",
    "code": "300630"
  },
  {
    "title": "普利制药2022年第一季度预计净利1.52亿-1.64亿同比增长25%-35% 市场开拓继续加强",
    "href": "http://stock.jrj.com.cn/2022/04/14051236329678.shtml",
    "datetime": "2022-04-14 05:12:11",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：一季度净利润预增25%-35%",
    "href": "http://stock.jrj.com.cn/2022/04/13203936326692.shtml",
    "datetime": "2022-04-13 20:39:31",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)业绩快报：2021年度净利增0.84%至4.11亿元",
    "href": "http://stock.jrj.com.cn/2022/04/13203736326695.shtml",
    "datetime": "2022-04-13 20:37:45",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：尚未实施股份回购",
    "href": "http://stock.jrj.com.cn/2022/04/01164636247570.shtml",
    "datetime": "2022-04-01 16:46:55",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：地氯雷他定片获得马来西亚上市许可",
    "href": "http://stock.jrj.com.cn/2022/03/17155534839214.shtml",
    "datetime": "2022-03-17 15:55:28",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用艾司奥美拉唑钠获得荷兰上市许可",
    "href": "http://stock.jrj.com.cn/2022/03/16173234834819.shtml",
    "datetime": "2022-03-16 17:32:50",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：拟使用不超2亿元闲置募集资金暂补流动资金",
    "href": "http://stock.jrj.com.cn/2022/03/15000634826400.shtml",
    "datetime": "2022-03-15 00:06:47",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：拟使用不超1.5亿元部分暂时闲置募集资金适时进行现金管理",
    "href": "http://stock.jrj.com.cn/2022/03/15000534826398.shtml",
    "datetime": "2022-03-15 00:05:16",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)截至2月底暂未回购股份",
    "href": "http://stock.jrj.com.cn/2022/03/02174634512797.shtml",
    "datetime": "2022-03-02 17:46:36",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用盐酸万古霉素获哥斯达黎加卫生部上市许可",
    "href": "http://stock.jrj.com.cn/2022/02/16184234370617.shtml",
    "datetime": "2022-02-16 18:42:53",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用伏立康唑获得英国药监机构(MHRA)上市许可",
    "href": "http://stock.jrj.com.cn/2022/02/15171334354207.shtml",
    "datetime": "2022-02-15 17:13:02",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：奥卡西平片通过荷兰药物评价委员会(CBG)技术审评",
    "href": "http://stock.jrj.com.cn/2022/02/14170934345068.shtml",
    "datetime": "2022-02-14 17:09:19",
    "code": "300630"
  },
  {
    "title": "普利制药将花不超1000万元回购公司股份 用于股权激励",
    "href": "http://stock.jrj.com.cn/2022/02/10211034319649.shtml",
    "datetime": "2022-02-10 21:10:51",
    "code": "300630"
  },
  {
    "title": "普利制药：拟500万-1000万元回购股份 回购价格不超过76.76元/股",
    "href": "http://stock.jrj.com.cn/2022/02/10195734319603.shtml",
    "datetime": "2022-02-10 19:57:03",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用艾司奥美拉唑钠通过荷兰药物评价委员会(CBG)技术审评",
    "href": "http://stock.jrj.com.cn/2022/02/10194234319304.shtml",
    "datetime": "2022-02-10 19:42:44",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：拟500万元-1000万元回购公司股份",
    "href": "http://stock.jrj.com.cn/2022/02/10193734319291.shtml",
    "datetime": "2022-02-10 19:37:43",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：参加国家重点研发计划纳米前沿重点专项2021年项目立项",
    "href": "http://stock.jrj.com.cn/2022/01/24181734205532.shtml",
    "datetime": "2022-01-24 18:17:37",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：氢氧化镁原料药DMF和CEP申请获FDA及EDQM接收",
    "href": "http://stock.jrj.com.cn/2022/01/23175334194515.shtml",
    "datetime": "2022-01-23 17:53:13",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：2022年度拟向银行和金融机构申请不超30亿元综合授信额度",
    "href": "http://stock.jrj.com.cn/2022/01/11221534147864.shtml",
    "datetime": "2022-01-11 22:15:22",
    "code": "300630"
  },
  {
    "title": "普利制药选举范敏华担任公司董事长 第三季度公司净利1.65亿",
    "href": "http://stock.jrj.com.cn/2021/12/20215034036855.shtml",
    "datetime": "2021-12-20 21:50:44",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用阿奇霉素获得英国药品注册批件",
    "href": "http://stock.jrj.com.cn/2021/12/19180334032674.shtml",
    "datetime": "2021-12-19 18:03:34",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：再次通过高新技术企业认定",
    "href": "http://stock.jrj.com.cn/2021/12/14173234014939.shtml",
    "datetime": "2021-12-14 17:32:45",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：地氯雷他定干混悬剂获荷兰上市许可",
    "href": "http://stock.jrj.com.cn/2021/12/07163733980336.shtml",
    "datetime": "2021-12-07 16:37:13",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：第二期员工持股计划累计买入59.5万股",
    "href": "http://stock.jrj.com.cn/2021/11/23155233909559.shtml",
    "datetime": "2021-11-23 15:52:13",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用盐酸万古霉素5g和10g获得美国FDA批准通知",
    "href": "http://stock.jrj.com.cn/2021/11/21211633894050.shtml",
    "datetime": "2021-11-21 21:16:52",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)注射用盐酸万古霉素5g和10g获得美国FDA批准通知",
    "href": "http://stock.jrj.com.cn/2021/11/21171133892832.shtml",
    "datetime": "2021-11-21 17:11:20",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：控股股东及一致行动人已减持“普利转债”共71.5749万张",
    "href": "http://stock.jrj.com.cn/2021/11/10202033832895.shtml",
    "datetime": "2021-11-10 20:20:38",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：实控人之一朱小平解押822万股",
    "href": "http://stock.jrj.com.cn/2021/11/05214833818349.shtml",
    "datetime": "2021-11-05 21:48:03",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：控股股东一致行动人已减持“普利转债”共105.1209万张",
    "href": "http://stock.jrj.com.cn/2021/11/05214633818337.shtml",
    "datetime": "2021-11-05 21:46:28",
    "code": "300630"
  },
  {
    "title": "普利制药：股东朱小平所持822万股解除质押",
    "href": "http://stock.jrj.com.cn/2021/11/05181333817759.shtml",
    "datetime": "2021-11-05 18:13:24",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：控股股东及一致行动人近日减持“普利转债”共50.0363万张",
    "href": "http://stock.jrj.com.cn/2021/11/01194133799448.shtml",
    "datetime": "2021-11-01 19:41:05",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用伏立康唑获得哥斯达黎加卫生部上市许可",
    "href": "http://stock.jrj.com.cn/2021/10/31163633784862.shtml",
    "datetime": "2021-10-31 16:36:35",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：第三季度净利润升30.50%至1.65亿元",
    "href": "http://stock.jrj.com.cn/2021/10/25185033748864.shtml",
    "datetime": "2021-10-25 18:50:59",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：第二期员工持股计划尚未购买公司股票",
    "href": "http://stock.jrj.com.cn/2021/10/22210733735524.shtml",
    "datetime": "2021-10-22 21:07:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：地氯雷他定干混悬剂获得德国上市许可",
    "href": "http://stock.jrj.com.cn/2021/10/21202433729156.shtml",
    "datetime": "2021-10-21 20:24:36",
    "code": "300630"
  },
  {
    "title": "普利制药2021年前三季度预计净利3.7亿元–4.13亿元 比上年同期增加30%–45%",
    "href": "http://stock.jrj.com.cn/2021/10/14171533691716.shtml",
    "datetime": "2021-10-14 17:15:07",
    "code": "300630"
  },
  {
    "title": "A股异动丨普利制药(300630.SZ)涨4.63% 旗下药品获在马来西亚销售资格",
    "href": "http://stock.jrj.com.cn/2021/10/11112733671973.shtml",
    "datetime": "2021-10-11 11:27:26",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：左乙拉西坦注射用浓溶液获得马来西亚药品管理局批准通知",
    "href": "http://stock.jrj.com.cn/2021/10/10235433664414.shtml",
    "datetime": "2021-10-10 23:54:43",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：实控人之一朱小平解押708万股",
    "href": "http://stock.jrj.com.cn/2021/10/10102533663199.shtml",
    "datetime": "2021-10-10 10:25:19",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用伏立康唑获得澳大利亚药物管理局上市许可",
    "href": "http://stock.jrj.com.cn/2021/10/07190733646822.shtml",
    "datetime": "2021-10-07 19:07:06",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：实控人已减持“普利转债”共121.619万张",
    "href": "http://stock.jrj.com.cn/2021/09/24220233511981.shtml",
    "datetime": "2021-09-24 22:02:54",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：55.56万股限制性股票将解除限售上市流通",
    "href": "http://stock.jrj.com.cn/2021/09/24220133511974.shtml",
    "datetime": "2021-09-24 22:01:15",
    "code": "300630"
  },
  {
    "title": "普利制药：本次限制性股票上市流通日为9月29日 占公司总股本0.1271%",
    "href": "http://stock.jrj.com.cn/2021/09/24201033511660.shtml",
    "datetime": "2021-09-24 20:10:33",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)与Celsion公司签订合作协议",
    "href": "http://stock.jrj.com.cn/2021/09/21180833488548.shtml",
    "datetime": "2021-09-21 18:08:02",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用比伐芦定获得英国药品和健康产品管理局(MHRA)上市许可",
    "href": "http://stock.jrj.com.cn/2021/09/21180633488547.shtml",
    "datetime": "2021-09-21 18:06:41",
    "code": "300630"
  },
  {
    "title": "普利制药：与Celsion公司签订DNA疫苗相关合作协议",
    "href": "http://stock.jrj.com.cn/2021/09/21173933487874.shtml",
    "datetime": "2021-09-21 17:39:35",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：可解除限售的限制性股票共55.56万股",
    "href": "http://stock.jrj.com.cn/2021/09/10164633415615.shtml",
    "datetime": "2021-09-10 16:46:24",
    "code": "300630"
  },
  {
    "title": "普利制药实际控制人朱小平质押1530万股 用于个人资金需求",
    "href": "http://stock.jrj.com.cn/2021/09/01222133369935.shtml",
    "datetime": "2021-09-01 22:21:54",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：实控人之一朱小平质押1530万股",
    "href": "http://stock.jrj.com.cn/2021/09/01204233369452.shtml",
    "datetime": "2021-09-01 20:42:11",
    "code": "300630"
  },
  {
    "title": "普利制药：地氯雷他定干混悬剂即将获荷兰和德国上市许可",
    "href": "http://stock.jrj.com.cn/2021/08/22174833294072.shtml",
    "datetime": "2021-08-22 17:48:35",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：地氯雷他定干混悬剂即将获荷兰和德国上市许可",
    "href": "http://stock.jrj.com.cn/2021/08/22174033294007.shtml",
    "datetime": "2021-08-22 17:40:35",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：“普利转债”将于8月23日起开始转股",
    "href": "http://stock.jrj.com.cn/2021/08/18202433275649.shtml",
    "datetime": "2021-08-18 20:24:08",
    "code": "300630"
  },
  {
    "title": "普利制药2021年半年度净利2.25亿元 同比净利增加42.06%",
    "href": "http://stock.jrj.com.cn/2021/08/11115333236579.shtml",
    "datetime": "2021-08-11 11:53:57",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：全资子公司安徽普利获得药品生产许可证",
    "href": "http://stock.jrj.com.cn/2021/08/10173033232268.shtml",
    "datetime": "2021-08-10 17:30:03",
    "code": "300630"
  },
  {
    "title": "普利制药2021年上半年净利2.25亿增长42.06% 销售收入增加",
    "href": "http://stock.jrj.com.cn/2021/08/09215433227518.shtml",
    "datetime": "2021-08-09 21:54:09",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)半年度净利润升42.06%至2.25亿元",
    "href": "http://stock.jrj.com.cn/2021/08/09194333226836.shtml",
    "datetime": "2021-08-09 19:43:50",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：与中科院高能所签署共建医药创新技术中心合作协议",
    "href": "http://stock.jrj.com.cn/2021/07/27163833158511.shtml",
    "datetime": "2021-07-27 16:38:30",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)收到依替巴肽注射液药品注册批件",
    "href": "http://stock.jrj.com.cn/2021/07/25165233145105.shtml",
    "datetime": "2021-07-25 16:52:54",
    "code": "300630"
  },
  {
    "title": "普利制药2021年上半年预计净利2.06亿-2.38亿增长30%-50% 国内外业务规模提升",
    "href": "http://stock.jrj.com.cn/2021/07/14194033096204.shtml",
    "datetime": "2021-07-14 19:40:41",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)上半年预盈2.06亿元-2.38亿元 同比增长30%-50%",
    "href": "http://stock.jrj.com.cn/2021/07/14162033095009.shtml",
    "datetime": "2021-07-14 16:20:41",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)双环胺注射液获得美国FDA生产批件",
    "href": "http://stock.jrj.com.cn/2021/07/04170933039561.shtml",
    "datetime": "2021-07-04 17:09:33",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)2020年度权益分派10派1.87元 股权登记日为7月8日",
    "href": "http://stock.jrj.com.cn/2021/07/01195933028860.shtml",
    "datetime": "2021-07-01 19:59:35",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用阿奇霉素拟中标第五批全国药品集采",
    "href": "http://stock.jrj.com.cn/2021/06/23183432984178.shtml",
    "datetime": "2021-06-23 18:34:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：左乙拉西坦注射用浓溶液在泰国获批",
    "href": "http://stock.jrj.com.cn/2021/06/21170732970136.shtml",
    "datetime": "2021-06-21 17:07:27",
    "code": "300630"
  },
  {
    "title": "普利制药：分散片制剂等独家剂型均为仿制药",
    "href": "http://stock.jrj.com.cn/2021/06/21141132969122.shtml",
    "datetime": "2021-06-21 14:11:45",
    "code": "300630"
  },
  {
    "title": "普利制药：公司正逐步从国际仿制药向国际创新药探索 并已聚焦于多个适应症领域稳步进行",
    "href": "http://stock.jrj.com.cn/2021/06/21140932969112.shtml",
    "datetime": "2021-06-21 14:09:10",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：特利加压素注射液在德获批上市",
    "href": "http://stock.jrj.com.cn/2021/06/09191232900936.shtml",
    "datetime": "2021-06-09 19:12:01",
    "code": "300630"
  },
  {
    "title": "普利制药：公司第三批全国药品集中采购中标品种包括地氯雷他定片、左乙拉西坦注射用浓溶液",
    "href": "http://stock.jrj.com.cn/2021/06/09093032897836.shtml",
    "datetime": "2021-06-09 09:30:05",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用泮托拉唑钠获得加拿大卫生部批准",
    "href": "http://stock.jrj.com.cn/2021/06/03181032870177.shtml",
    "datetime": "2021-06-03 18:10:29",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：射用比伐芦定获得美国FDA正式批准",
    "href": "http://stock.jrj.com.cn/2021/05/30175132841355.shtml",
    "datetime": "2021-05-30 17:51:33",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：董事亲属买卖公司可转债构成短线交易",
    "href": "http://stock.jrj.com.cn/2021/05/21214532795291.shtml",
    "datetime": "2021-05-21 21:45:56",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用阿奇霉素获得新西兰上市许可",
    "href": "http://stock.jrj.com.cn/2021/05/05184832679001.shtml",
    "datetime": "2021-05-05 18:48:30",
    "code": "300630"
  },
  {
    "title": "普利制药：中美关系局势对公司业务暂无影响",
    "href": "http://stock.jrj.com.cn/2021/04/26101532452297.shtml",
    "datetime": "2021-04-26 10:15:44",
    "code": "300630"
  },
  {
    "title": "普利制药2021年第一季度净利1.21亿增长51.4% 国内外药品销售加大拓展",
    "href": "http://stock.jrj.com.cn/2021/04/24204032435864.shtml",
    "datetime": "2021-04-24 20:40:16",
    "code": "300630"
  },
  {
    "title": "普利制药2020年净利4.07亿增长35.3% 董事长范敏华薪酬57.62万",
    "href": "http://stock.jrj.com.cn/2021/04/24200332435735.shtml",
    "datetime": "2021-04-24 20:03:10",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)一季度净利升51.40%至1.21亿元",
    "href": "http://stock.jrj.com.cn/2021/04/24123632434998.shtml",
    "datetime": "2021-04-24 12:36:49",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)2020年净利升35.30%至4.07亿元 拟10派1.87元",
    "href": "http://stock.jrj.com.cn/2021/04/24123432434996.shtml",
    "datetime": "2021-04-24 12:34:12",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)500mg左氧氟沙星片获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2021/04/18170232393482.shtml",
    "datetime": "2021-04-18 17:02:45",
    "code": "300630"
  },
  {
    "title": "普利制药2021年第一季度预计净利增长30%-50% 经营业绩稳步提升",
    "href": "http://stock.jrj.com.cn/2021/04/14144732371464.shtml",
    "datetime": "2021-04-14 14:47:06",
    "code": "300630"
  },
  {
    "title": "A股异动 | 普利制药(300630.SZ)涨近5% 一季度净利润预增30%-50%",
    "href": "http://stock.jrj.com.cn/2021/04/14111032370158.shtml",
    "datetime": "2021-04-14 11:10:06",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)一季度净利润预增30%-50%",
    "href": "http://stock.jrj.com.cn/2021/04/13222332367300.shtml",
    "datetime": "2021-04-13 22:23:44",
    "code": "300630"
  },
  {
    "title": "普利制药股东综合制药减持2059.84万股 套现约8.29亿",
    "href": "http://stock.jrj.com.cn/2021/04/09220032344875.shtml",
    "datetime": "2021-04-09 22:00:23",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：综合制药已累计减持4.7343%的股份",
    "href": "http://stock.jrj.com.cn/2021/04/08192132333591.shtml",
    "datetime": "2021-04-08 19:21:13",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：500mg注射用更昔洛韦获得意大利药品监管局上市许可",
    "href": "http://stock.jrj.com.cn/2021/03/31182332257341.shtml",
    "datetime": "2021-03-31 18:23:47",
    "code": "300630"
  },
  {
    "title": "普利制药：公司国际主要以经销商的方式进行销售",
    "href": "http://stock.jrj.com.cn/2021/03/29132832240236.shtml",
    "datetime": "2021-03-29 13:28:42",
    "code": "300630"
  },
  {
    "title": "普利制药：公司所有的应收账款控制在正常的账期内未发生坏账风险",
    "href": "http://stock.jrj.com.cn/2021/03/29130432240130.shtml",
    "datetime": "2021-03-29 13:04:17",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：拟使用部分暂时闲置募集资金适时进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/03/12165032115796.shtml",
    "datetime": "2021-03-12 16:50:18",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：拟使用不超2亿元闲置募集资金暂补流动资金",
    "href": "http://stock.jrj.com.cn/2021/03/12164932115787.shtml",
    "datetime": "2021-03-12 16:49:24",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：8.5亿元可转债将于3月8日起在深交所挂牌交易",
    "href": "http://stock.jrj.com.cn/2021/03/03205432065592.shtml",
    "datetime": "2021-03-03 20:54:26",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用比伐芦定美国专利挑战成功",
    "href": "http://stock.jrj.com.cn/2021/03/02162132057675.shtml",
    "datetime": "2021-03-02 16:21:06",
    "code": "300630"
  },
  {
    "title": "普利制药：知名药物研发高新技术企业 近期发行8.5亿可转债",
    "href": "http://stock.jrj.com.cn/2021/02/23181532013511.shtml",
    "datetime": "2021-02-23 18:15:23",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：特利加压素注射液获得荷兰药物评价委员会(CBG)上市许可",
    "href": "http://stock.jrj.com.cn/2021/02/23171932013053.shtml",
    "datetime": "2021-02-23 17:19:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)可转债网上中签结果出炉：中签号共22.5915万个",
    "href": "http://stock.jrj.com.cn/2021/02/17161231974194.shtml",
    "datetime": "2021-02-17 16:12:06",
    "code": "300630"
  },
  {
    "title": "普利制药：产能释放推动新一轮高速成长",
    "href": "http://stock.jrj.com.cn/2021/01/29213631811932.shtml",
    "datetime": "2021-01-29 21:36:00",
    "code": "300630"
  },
  {
    "title": "普利制药2020年预计净利3.91亿-4.37亿增长30%-45% 药品研发不断加强",
    "href": "http://stock.jrj.com.cn/2021/01/25211931768815.shtml",
    "datetime": "2021-01-25 21:19:55",
    "code": "300630"
  },
  {
    "title": "[普利制药]喜讯!热烈庆祝浙江普利通过美国FDA检查",
    "href": "http://stock.jrj.com.cn/2021/01/25000031766754.shtml",
    "datetime": "2021-01-25 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)及全资子公司拟向银行申请不超20亿元综合授信额度",
    "href": "http://stock.jrj.com.cn/2021/01/20184531730488.shtml",
    "datetime": "2021-01-20 18:45:18",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)及全资子公司拟开展外汇衍生品交易业务",
    "href": "http://stock.jrj.com.cn/2021/01/20184331730485.shtml",
    "datetime": "2021-01-20 18:43:38",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：特利加压素注射液通过荷兰药物评价委员会(CBG)技术审评",
    "href": "http://stock.jrj.com.cn/2021/01/19160731722049.shtml",
    "datetime": "2021-01-19 16:07:46",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：发行可转债申请获证监会同意注册批复",
    "href": "http://stock.jrj.com.cn/2021/01/14194931693472.shtml",
    "datetime": "2021-01-14 19:49:12",
    "code": "300630"
  },
  {
    "title": "普利制药：公司安庆原料药项目正在积极抓紧建设",
    "href": "http://stock.jrj.com.cn/2021/01/14090931688740.shtml",
    "datetime": "2021-01-14 09:09:49",
    "code": "300630"
  },
  {
    "title": "[普利制药]安徽普利药业顺利完成2021年度安全责任状签订工作",
    "href": "http://stock.jrj.com.cn/2021/01/14000031691946.shtml",
    "datetime": "2021-01-14 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用更昔洛韦钠首家通过仿制药一致性评价",
    "href": "http://stock.jrj.com.cn/2020/12/29212131597564.shtml",
    "datetime": "2020-12-29 21:21:18",
    "code": "300630"
  },
  {
    "title": "[普利制药]国内首家,普利注射用更昔洛韦钠通过一致性评价",
    "href": "http://stock.jrj.com.cn/2020/12/29000031643018.shtml",
    "datetime": "2020-12-29 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：股东综合制药减持比例达到1%",
    "href": "http://stock.jrj.com.cn/2020/12/25185131571662.shtml",
    "datetime": "2020-12-25 18:51:21",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：8月18日以来累计收到政府补助5743.41万元",
    "href": "http://stock.jrj.com.cn/2020/12/24202931563519.shtml",
    "datetime": "2020-12-24 20:29:33",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：累计收到各项政府补助资金共5743.41万元",
    "href": "http://stock.jrj.com.cn/2020/12/24194831563272.shtml",
    "datetime": "2020-12-24 19:48:20",
    "code": "300630"
  },
  {
    "title": "普利制药：公司与浙大的项目进展顺利",
    "href": "http://stock.jrj.com.cn/2020/12/01162931385395.shtml",
    "datetime": "2020-12-01 16:29:39",
    "code": "300630"
  },
  {
    "title": "普利制药：公司多个儿童药项目都在如期进行",
    "href": "http://stock.jrj.com.cn/2020/12/01161231385235.shtml",
    "datetime": "2020-12-01 16:12:23",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：左乙拉西坦注射用浓溶液获得西班牙药品医疗器械管理局上市许可",
    "href": "http://stock.jrj.com.cn/2020/11/29173131368080.shtml",
    "datetime": "2020-11-29 17:31:41",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：注射用兰索拉唑获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/11/29173031368081.shtml",
    "datetime": "2020-11-29 17:30:25",
    "code": "300630"
  },
  {
    "title": "普利制药：公司药品获得西班牙药品医疗器械管理局上市许可",
    "href": "http://stock.jrj.com.cn/2020/11/29171531367909.shtml",
    "datetime": "2020-11-29 17:15:25",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用兰索拉唑获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/11/29163931367814.shtml",
    "datetime": "2020-11-29 16:39:50",
    "code": "300630"
  },
  {
    "title": "[普利制药]普利制药注射用伏立康唑、注射用万古霉素产能于针剂二车间放大后首发出口美国",
    "href": "http://stock.jrj.com.cn/2020/11/27000031373032.shtml",
    "datetime": "2020-11-27 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药前三季度净利2.85亿增长38.30% 政府拨款摊销增加",
    "href": "http://stock.jrj.com.cn/2020/11/02095931198612.shtml",
    "datetime": "2020-11-02 09:59:50",
    "code": "300630"
  },
  {
    "title": "[普利制药]心系儿童,普利制药作为核心企业成员入盟中国儿童药物研发与产业化联盟",
    "href": "http://stock.jrj.com.cn/2020/10/26000031134129.shtml",
    "datetime": "2020-10-26 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：左乙拉西坦注射用浓溶液获西班牙药品医疗器械管理局技术评审",
    "href": "http://stock.jrj.com.cn/2020/10/18173831075519.shtml",
    "datetime": "2020-10-18 17:38:44",
    "code": "300630"
  },
  {
    "title": "普利制药2020年前三季度净利2.47亿至2.88亿 国内外业务规模稳步提升",
    "href": "http://stock.jrj.com.cn/2020/10/15120331059072.shtml",
    "datetime": "2020-10-15 12:03:54",
    "code": "300630"
  },
  {
    "title": "普利制药：2020年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/10/14201031053468.shtml",
    "datetime": "2020-10-14 20:10:04",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：前三季度净利预增20%-40%",
    "href": "http://stock.jrj.com.cn/2020/10/14171431052443.shtml",
    "datetime": "2020-10-14 17:14:15",
    "code": "300630"
  },
  {
    "title": "A股异动 | 普利制药(300630.SZ)大涨9.68% 针剂三车间通过美国FDA审计",
    "href": "http://stock.jrj.com.cn/2020/10/12095531030466.shtml",
    "datetime": "2020-10-12 09:55:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]普利制药硝普钠注射液首单出口美国",
    "href": "http://stock.jrj.com.cn/2020/10/12000031032415.shtml",
    "datetime": "2020-10-12 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]普利制药这款已在欧洲上市的注射用比伐芦定中国获批上市",
    "href": "http://stock.jrj.com.cn/2020/10/12000031032420.shtml",
    "datetime": "2020-10-12 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)针剂三车间通过美国FDA审计",
    "href": "http://stock.jrj.com.cn/2020/10/11180831019517.shtml",
    "datetime": "2020-10-11 18:08:11",
    "code": "300630"
  },
  {
    "title": "普利制药2名股东合计减持1046.38万股 套现约4.33亿元",
    "href": "http://stock.jrj.com.cn/2020/09/25213330837513.shtml",
    "datetime": "2020-09-25 21:33:47",
    "code": "300630"
  },
  {
    "title": "普利制药澄清媒体：受检批次的生产留样药品干燥失重符合规定 不合格的药品抽样来自药品经营环节",
    "href": "http://stock.jrj.com.cn/2020/09/11205530732369.shtml",
    "datetime": "2020-09-11 20:55:21",
    "code": "300630"
  },
  {
    "title": "A股异动 | 普利制药(300630.SZ)跌逾4% 持股4.8348%的股东综合制药拟清仓减持",
    "href": "http://stock.jrj.com.cn/2020/09/10144630721727.shtml",
    "datetime": "2020-09-10 14:46:09",
    "code": "300630"
  },
  {
    "title": "普利制药股东综合制药减持1392.3万股 套现约8.23亿元",
    "href": "http://stock.jrj.com.cn/2020/09/07171930694319.shtml",
    "datetime": "2020-09-07 17:19:48",
    "code": "300630"
  },
  {
    "title": "普利制药(300630.SZ)：减持期届满 综合制药减持4.882%公司股份 持股跌出5%",
    "href": "http://stock.jrj.com.cn/2020/09/04201130678634.shtml",
    "datetime": "2020-09-04 20:11:41",
    "code": "300630"
  },
  {
    "title": "[普利制药]普利制药与浙江大学技术转让 签约仪式圆满完成",
    "href": "http://stock.jrj.com.cn/2020/09/01000030835850.shtml",
    "datetime": "2020-09-01 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药2020年上半年净利1.58亿增长31.97% 推广活动减少",
    "href": "http://stock.jrj.com.cn/2020/08/27203230606553.shtml",
    "datetime": "2020-08-27 20:32:47",
    "code": "300630"
  },
  {
    "title": "【龙虎榜】普利制药8月20日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/08/20180030550656.shtml",
    "datetime": "2020-08-20 18:00:23",
    "code": "300630"
  },
  {
    "title": "龙虎榜：赵老哥接盘君正集团 3机构抱团买入普利制药",
    "href": "http://stock.jrj.com.cn/hotstock/2020/08/20173630550484.shtml",
    "datetime": "2020-08-20 17:36:54",
    "code": "300630"
  },
  {
    "title": "[普利制药]乘风破浪,景同科技与SAP携手助力普利制药信息化建设",
    "href": "http://stock.jrj.com.cn/2020/08/20000030835851.shtml",
    "datetime": "2020-08-20 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药：2020年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/07/15083030245881.shtml",
    "datetime": "2020-07-15 08:30:10",
    "code": "300630"
  },
  {
    "title": "普利制药2020年上半年预计净利1.44亿元–1.62亿元 国内外业务稳步提升",
    "href": "http://stock.jrj.com.cn/2020/07/14235830242178.shtml",
    "datetime": "2020-07-14 23:58:20",
    "code": "300630"
  },
  {
    "title": "普利制药股东瑞康投资合计减持488万股 套现约3.83亿元",
    "href": "http://stock.jrj.com.cn/2020/07/10224730208239.shtml",
    "datetime": "2020-07-10 22:47:33",
    "code": "300630"
  },
  {
    "title": "普利制药拟发不超8.5亿可转债扩产 获批产品放量去年海外业务营收增135%",
    "href": "http://stock.jrj.com.cn/2020/07/06073430164533.shtml",
    "datetime": "2020-07-06 07:34:23",
    "code": "300630"
  },
  {
    "title": "普利制药拟向不特定对象发行可转债募资不超8.5亿元",
    "href": "http://stock.jrj.com.cn/2020/06/24183930011522.shtml",
    "datetime": "2020-06-24 18:39:31",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用比伐芦定获得德国联邦药物和医疗器械管理局上市许可",
    "href": "http://stock.jrj.com.cn/2020/06/17185329950879.shtml",
    "datetime": "2020-06-17 18:53:55",
    "code": "300630"
  },
  {
    "title": "普利制药拟投资设立孙公司 注册资本2000万元",
    "href": "http://stock.jrj.com.cn/2020/05/25222129762559.shtml",
    "datetime": "2020-05-25 22:21:28",
    "code": "300630"
  },
  {
    "title": "普利制药2020年一季度盈利8008.09万 同比增长14.38%",
    "href": "http://stock.jrj.com.cn/2020/05/02180429467529.shtml",
    "datetime": "2020-05-02 18:04:27",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用更昔洛韦钠获得泰国上市许可",
    "href": "http://stock.jrj.com.cn/2020/04/23165929359157.shtml",
    "datetime": "2020-04-23 16:59:00",
    "code": "300630"
  },
  {
    "title": "普利制药：2019年净利同比增65.99% 拟10转5.5派2.2元",
    "href": "http://stock.jrj.com.cn/2020/04/20214229331751.shtml",
    "datetime": "2020-04-20 21:42:00",
    "code": "300630"
  },
  {
    "title": "普利制药2020年一季度预计净利7701.64万元—8401.79万元 同比增长10%—20%",
    "href": "http://stock.jrj.com.cn/2020/04/10000729250598.shtml",
    "datetime": "2020-04-10 00:07:19",
    "code": "300630"
  },
  {
    "title": "[普利制药]不“减员”,不“断粮”,海南普利制药全力复产保障抗疫“弹药”支援一线",
    "href": "http://stock.jrj.com.cn/2020/03/15000029029365.shtml",
    "datetime": "2020-03-15 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药2019年净利3亿增长65% 积极拓展国际和国内市场销售",
    "href": "http://stock.jrj.com.cn/2020/02/26182828898492.shtml",
    "datetime": "2020-02-26 18:28:43",
    "code": "300630"
  },
  {
    "title": "普利制药：2019年净利3亿元 同比增长65%",
    "href": "http://stock.jrj.com.cn/2020/02/26162528897793.shtml",
    "datetime": "2020-02-26 16:25:54",
    "code": "300630"
  },
  {
    "title": "普利制药：再次修订非公开发行股票方案",
    "href": "http://stock.jrj.com.cn/2020/02/18173028849309.shtml",
    "datetime": "2020-02-18 17:30:00",
    "code": "300630"
  },
  {
    "title": "普利制药股东综合制药拟减持股份不超1649万股 占总股本6%",
    "href": "http://stock.jrj.com.cn/2020/02/16200428835247.shtml",
    "datetime": "2020-02-16 20:04:10",
    "code": "300630"
  },
  {
    "title": "普利制药：股东综合制药拟减持不超6%股份",
    "href": "http://stock.jrj.com.cn/2020/02/14190328831081.shtml",
    "datetime": "2020-02-14 19:03:00",
    "code": "300630"
  },
  {
    "title": "普利制药：持股9.72%的股东拟减持不超6%股份",
    "href": "http://stock.jrj.com.cn/2020/02/14185128831046.shtml",
    "datetime": "2020-02-14 18:51:59",
    "code": "300630"
  },
  {
    "title": "普利制药：股东拟减持不超过6%公司股份",
    "href": "http://stock.jrj.com.cn/2020/02/14184628831005.shtml",
    "datetime": "2020-02-14 18:46:29",
    "code": "300630"
  },
  {
    "title": "[普利制药]陆续抵达前线,普利制药捐赠药品获肯定",
    "href": "http://stock.jrj.com.cn/2020/02/06000028786930.shtml",
    "datetime": "2020-02-06 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]普利制药开足马力生产,全力保障疫情用药供应",
    "href": "http://stock.jrj.com.cn/2020/02/06000028782455.shtml",
    "datetime": "2020-02-06 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]山东省红十字会接受普利制药为山东疫情定向捐赠价值148万元注射用阿奇霉素",
    "href": "http://stock.jrj.com.cn/2020/02/06000028785513.shtml",
    "datetime": "2020-02-06 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]普利制药抗击武汉肺炎防控知识手册",
    "href": "http://stock.jrj.com.cn/2020/02/05000028779205.shtml",
    "datetime": "2020-02-05 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用更昔洛韦钠获得塞浦路斯上市许可",
    "href": "http://stock.jrj.com.cn/2020/02/04194128768393.shtml",
    "datetime": "2020-02-04 19:41:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]海南普利制药股份有限公司关于注射用更昔洛韦钠获得塞浦路斯上市许可的公告",
    "href": "http://stock.jrj.com.cn/2020/02/04000028774654.shtml",
    "datetime": "2020-02-04 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]疫情紧急,普利继续全力保障捐赠药品配达医院",
    "href": "http://stock.jrj.com.cn/2020/02/04000028774655.shtml",
    "datetime": "2020-02-04 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]火速驰援,普利注射用阿奇霉素已送达金银潭、肺科等武汉33家医院",
    "href": "http://stock.jrj.com.cn/2020/02/03000028752341.shtml",
    "datetime": "2020-02-03 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]阿奇霉素纳入各地防控用药,普利捐赠陆续抵达各定点医院",
    "href": "http://stock.jrj.com.cn/2020/02/01000028768839.shtml",
    "datetime": "2020-02-01 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]大年初七,普利制药继续向全国疫区驰援",
    "href": "http://stock.jrj.com.cn/2020/01/31000028768837.shtml",
    "datetime": "2020-01-31 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]普利制药持续向安徽河北等地驰援,累计捐赠2082万元防治药品",
    "href": "http://stock.jrj.com.cn/2020/01/30000028750167.shtml",
    "datetime": "2020-01-30 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]阿奇霉素|肺炎防治中具有积极作用",
    "href": "http://stock.jrj.com.cn/2020/01/26000028768807.shtml",
    "datetime": "2020-01-26 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]战胜疫情,普利在行动,武汉我们来了!",
    "href": "http://stock.jrj.com.cn/2020/01/24000028768836.shtml",
    "datetime": "2020-01-24 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]战胜疫情,普利在行动,湖南今日首捐",
    "href": "http://stock.jrj.com.cn/2020/01/23000028768835.shtml",
    "datetime": "2020-01-23 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]家国情怀,普利制药为武汉疫情做好药品保障供应与爱心奉献准备!",
    "href": "http://stock.jrj.com.cn/2020/01/21000028768838.shtml",
    "datetime": "2020-01-21 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]新型冠状病毒:如何保护自己和家人且看WHO权威解读",
    "href": "http://stock.jrj.com.cn/2020/01/20000028768834.shtml",
    "datetime": "2020-01-20 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药：2019年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/01/14170028675737.shtml",
    "datetime": "2020-01-14 17:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药2019年度预计净利2.72亿元–3.08亿元 同比增长50%-70%",
    "href": "http://stock.jrj.com.cn/2020/01/14162528675562.shtml",
    "datetime": "2020-01-14 16:25:49",
    "code": "300630"
  },
  {
    "title": "普利制药：2019年净利同比预增50%-70%",
    "href": "http://stock.jrj.com.cn/2020/01/14160728675464.shtml",
    "datetime": "2020-01-14 16:07:00",
    "code": "300630"
  },
  {
    "title": "普利制药：2019年度净利同比预增50%-70%",
    "href": "http://stock.jrj.com.cn/2020/01/14155628675427.shtml",
    "datetime": "2020-01-14 15:56:56",
    "code": "300630"
  },
  {
    "title": "普利制药：坚持差异化研发 打造全球价值产业链",
    "href": "http://stock.jrj.com.cn/2019/12/26213528592395.shtml",
    "datetime": "2019-12-26 21:35:00",
    "code": "300630"
  },
  {
    "title": "普利制药：国家集采对于公司利润的影响可控",
    "href": "http://stock.jrj.com.cn/2019/12/26160828590828.shtml",
    "datetime": "2019-12-26 16:08:00",
    "code": "300630"
  },
  {
    "title": "普利制药：将适时考虑布局创新药",
    "href": "http://stock.jrj.com.cn/2019/12/26155028590780.shtml",
    "datetime": "2019-12-26 15:50:00",
    "code": "300630"
  },
  {
    "title": "普利制药：随着国内注射剂一致性评价加速开展 后续大量品种将实现国内国外同步上市",
    "href": "http://stock.jrj.com.cn/2019/12/26155028590781.shtml",
    "datetime": "2019-12-26 15:50:00",
    "code": "300630"
  },
  {
    "title": "普利制药：抗生素和抗过敏药物占营收比重超60%",
    "href": "http://stock.jrj.com.cn/2019/12/26153528590753.shtml",
    "datetime": "2019-12-26 15:35:00",
    "code": "300630"
  },
  {
    "title": "普利制药：地氯雷他定片刚刚通过一致性评价 将有利于产品市场销售",
    "href": "http://stock.jrj.com.cn/2019/12/26153328590741.shtml",
    "datetime": "2019-12-26 15:33:00",
    "code": "300630"
  },
  {
    "title": "普利制药下半年以来累计收到政府补助1838万元",
    "href": "http://stock.jrj.com.cn/2019/12/25224728587179.shtml",
    "datetime": "2019-12-25 22:47:43",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用比伐芦定获得荷兰药物评价委员会上市许可",
    "href": "http://stock.jrj.com.cn/2019/12/19190628558139.shtml",
    "datetime": "2019-12-19 19:06:40",
    "code": "300630"
  },
  {
    "title": "普利制药：持股4%的股东拟清仓减持",
    "href": "http://stock.jrj.com.cn/2019/12/18181428552060.shtml",
    "datetime": "2019-12-18 18:14:04",
    "code": "300630"
  },
  {
    "title": "普利制药：地氯雷他定片获得荷兰药物评价委员会上市许可",
    "href": "http://stock.jrj.com.cn/2019/12/18181228552141.shtml",
    "datetime": "2019-12-18 18:12:00",
    "code": "300630"
  },
  {
    "title": "普利制药：地氯雷他定片获荷兰药物评价委员会上市许可",
    "href": "http://stock.jrj.com.cn/2019/12/18174128551966.shtml",
    "datetime": "2019-12-18 17:41:53",
    "code": "300630"
  },
  {
    "title": "普利制药：股东瑞康投资拟减持不超过2%股份",
    "href": "http://stock.jrj.com.cn/2019/12/18172528551887.shtml",
    "datetime": "2019-12-18 17:25:22",
    "code": "300630"
  },
  {
    "title": "普利制药非公开发行股票获证监会核准批复",
    "href": "http://stock.jrj.com.cn/2019/12/02194728479375.shtml",
    "datetime": "2019-12-02 19:47:05",
    "code": "300630"
  },
  {
    "title": "普利制药：子公司获得药品生产许可证",
    "href": "http://stock.jrj.com.cn/2019/11/25160728447807.shtml",
    "datetime": "2019-11-25 16:07:45",
    "code": "300630"
  },
  {
    "title": "普利制药：地氯雷他定片（5mg）通过一致性评价",
    "href": "http://stock.jrj.com.cn/2019/11/24172828442512.shtml",
    "datetime": "2019-11-24 17:28:09",
    "code": "300630"
  },
  {
    "title": "[普利制药]喜讯!芙必叮成为国内首个在欧盟获批上市的地氯雷他定片",
    "href": "http://stock.jrj.com.cn/2019/11/22000028436918.shtml",
    "datetime": "2019-11-22 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]普利国际高端生产线扩建项目奠基开工仪式隆重举行",
    "href": "http://stock.jrj.com.cn/2019/11/22000028573646.shtml",
    "datetime": "2019-11-22 00:00:00",
    "code": "300630"
  },
  {
    "title": "[普利制药]浙江普利药业有限公司获得欧盟人用药品GMP证书",
    "href": "http://stock.jrj.com.cn/2019/10/31000028335663.shtml",
    "datetime": "2019-10-31 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药第三季度盈利8595万 同比增长71%",
    "href": "http://stock.jrj.com.cn/2019/10/25164228300729.shtml",
    "datetime": "2019-10-25 16:42:27",
    "code": "300630"
  },
  {
    "title": "普利制药：2019年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/10/10201028228534.shtml",
    "datetime": "2019-10-10 20:10:00",
    "code": "300630"
  },
  {
    "title": "普利制药2019年前三季度净利1.94亿–2.06亿 国内外业务规模稳步提升",
    "href": "http://stock.jrj.com.cn/2019/10/10182728227905.shtml",
    "datetime": "2019-10-10 18:27:03",
    "code": "300630"
  },
  {
    "title": "普利制药：前三季净利预增60%-70%",
    "href": "http://stock.jrj.com.cn/2019/10/10161128227165.shtml",
    "datetime": "2019-10-10 16:11:45",
    "code": "300630"
  },
  {
    "title": "普利制药：前三季净利预增60%-70%",
    "href": "http://stock.jrj.com.cn/2019/10/10160128227155.shtml",
    "datetime": "2019-10-10 16:01:00",
    "code": "300630"
  },
  {
    "title": "普利制药：前三季度净利预增60%-70%",
    "href": "http://stock.jrj.com.cn/2019/10/10155228227105.shtml",
    "datetime": "2019-10-10 15:52:06",
    "code": "300630"
  },
  {
    "title": "普利制药监事会主席衷兴华辞职",
    "href": "http://stock.jrj.com.cn/2019/09/20184328161304.shtml",
    "datetime": "2019-09-20 18:43:59",
    "code": "300630"
  },
  {
    "title": "普利制药：非公开发行股票申请获证监会审核通过",
    "href": "http://stock.jrj.com.cn/2019/09/09220828111449.shtml",
    "datetime": "2019-09-09 22:08:56",
    "code": "300630"
  },
  {
    "title": "普利制药：非公开发行股票申请获审核通过",
    "href": "http://stock.jrj.com.cn/2019/09/09213328111332.shtml",
    "datetime": "2019-09-09 21:33:08",
    "code": "300630"
  },
  {
    "title": "普利制药、捷捷微电非公开发行申请获证监会通过",
    "href": "http://stock.jrj.com.cn/2019/09/09162128109822.shtml",
    "datetime": "2019-09-09 16:21:00",
    "code": "300630"
  },
  {
    "title": "普利制药2019年上半年营收3.52亿 产品出货价格相对较高",
    "href": "http://stock.jrj.com.cn/2019/08/22191128018315.shtml",
    "datetime": "2019-08-22 19:11:59",
    "code": "300630"
  },
  {
    "title": "海南证监局等赴普利制药、京粮控股、大华股份开展调研活动",
    "href": "http://stock.jrj.com.cn/2019/07/17150527852194.shtml",
    "datetime": "2019-07-17 15:05:00",
    "code": "300630"
  },
  {
    "title": "普利制药2019年上半年净利1.12亿–1.2亿 同比增长60%-70%",
    "href": "http://stock.jrj.com.cn/2019/07/13103627836347.shtml",
    "datetime": "2019-07-13 10:36:22",
    "code": "300630"
  },
  {
    "title": "普利制药：上半年净利预增60%-70%",
    "href": "http://stock.jrj.com.cn/2019/07/12221727834309.shtml",
    "datetime": "2019-07-12 22:17:00",
    "code": "300630"
  },
  {
    "title": "普利制药：瑞康投资累计减持1.17%的股份",
    "href": "http://stock.jrj.com.cn/2019/06/26164227758899.shtml",
    "datetime": "2019-06-26 16:42:02",
    "code": "300630"
  },
  {
    "title": "普利制药：瑞康投资减持公司1.17%股份",
    "href": "http://stock.jrj.com.cn/2019/06/26155027758649.shtml",
    "datetime": "2019-06-26 15:50:00",
    "code": "300630"
  },
  {
    "title": "普利制药副总经理沈世华辞职 薪酬20万元",
    "href": "http://stock.jrj.com.cn/2019/06/11075027684733.shtml",
    "datetime": "2019-06-11 07:50:40",
    "code": "300630"
  },
  {
    "title": "[普利制药]国际高端原料药及创新制剂制造基地―安徽普利生物药业奠基暨开工仪式盛大举行!",
    "href": "http://stock.jrj.com.cn/2019/06/01000027655293.shtml",
    "datetime": "2019-06-01 00:00:00",
    "code": "300630"
  },
  {
    "title": "普利制药：减持计划届满 瑞康投资拟继续减持不超5.56%股份",
    "href": "http://stock.jrj.com.cn/2019/05/29180727638428.shtml",
    "datetime": "2019-05-29 18:07:00",
    "code": "300630"
  },
  {
    "title": "普利制药：持股5.56%的股东拟在6个月内减持不超2%",
    "href": "http://stock.jrj.com.cn/2019/05/29173427638121.shtml",
    "datetime": "2019-05-29 17:34:32",
    "code": "300630"
  },
  {
    "title": "普利制药拟定增逾5亿投建原料药制造基地 预计建成后年产360吨原料药",
    "href": "http://stock.jrj.com.cn/2019/05/21204327602938.shtml",
    "datetime": "2019-05-21 20:43:00",
    "code": "300630"
  },
  {
    "title": "普利制药：拟定增募资用于高端原料药及创新制剂制造基地项目",
    "href": "http://stock.jrj.com.cn/2019/05/21175127602408.shtml",
    "datetime": "2019-05-21 17:51:00",
    "code": "300630"
  },
  {
    "title": "普利制药：拟定增募资不超5.52亿元 投建高端原料药项目",
    "href": "http://stock.jrj.com.cn/2019/05/21171627602049.shtml",
    "datetime": "2019-05-21 17:16:59",
    "code": "300630"
  },
  {
    "title": "普利制药：员工持股计划清仓减持近90.3万股股份",
    "href": "http://stock.jrj.com.cn/2019/05/13180827564793.shtml",
    "datetime": "2019-05-13 18:08:31",
    "code": "300630"
  },
  {
    "title": "普利制药注射用阿奇霉素通过马来西亚药品管理局技术评审",
    "href": "http://stock.jrj.com.cn/2019/05/12171827558255.shtml",
    "datetime": "2019-05-12 17:18:27",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用阿奇霉素通过马来西亚药品管理局技术评审",
    "href": "http://stock.jrj.com.cn/2019/05/12164427558203.shtml",
    "datetime": "2019-05-12 16:44:00",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用阿奇霉素获澳大利亚上市许可",
    "href": "http://stock.jrj.com.cn/2019/05/08180627543577.shtml",
    "datetime": "2019-05-08 18:06:53",
    "code": "300630"
  },
  {
    "title": "普利制药：公司注射用阿奇霉素获得澳大利亚上市许可",
    "href": "http://stock.jrj.com.cn/2019/05/08180127543566.shtml",
    "datetime": "2019-05-08 18:01:00",
    "code": "300630"
  },
  {
    "title": "普利制药：一季度净利7001万元 同比增长125%",
    "href": "http://stock.jrj.com.cn/2019/04/22172127455144.shtml",
    "datetime": "2019-04-22 17:21:19",
    "code": "300630"
  },
  {
    "title": "普利制药：抗真菌药伏立康唑获准在德国上市",
    "href": "http://stock.jrj.com.cn/2019/04/21164227442710.shtml",
    "datetime": "2019-04-21 16:42:58",
    "code": "300630"
  },
  {
    "title": "普利制药去年净利1.81亿同比增84% 董事长范敏华年薪45万",
    "href": "http://stock.jrj.com.cn/2019/04/02190427308980.shtml",
    "datetime": "2019-04-02 19:04:44",
    "code": "300630"
  },
  {
    "title": "普利制药：2019年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/04/01223027297426.shtml",
    "datetime": "2019-04-01 22:30:00",
    "code": "300630"
  },
  {
    "title": "普利制药：2018年年度报告主要财务指标及分配预案",
    "href": "http://stock.jrj.com.cn/2019/04/01204027296680.shtml",
    "datetime": "2019-04-01 20:40:00",
    "code": "300630"
  },
  {
    "title": "普利制药2018年净利增84% 拟10转5派2.1元",
    "href": "http://stock.jrj.com.cn/2019/04/01201627296485.shtml",
    "datetime": "2019-04-01 20:16:46",
    "code": "300630"
  },
  {
    "title": "普利制药：一季度净利预增100%-125%",
    "href": "http://stock.jrj.com.cn/2019/04/01201427296481.shtml",
    "datetime": "2019-04-01 20:14:20",
    "code": "300630"
  },
  {
    "title": "普利制药：2018年净利增84% 拟10转5派2.1元",
    "href": "http://stock.jrj.com.cn/2019/04/01195527296386.shtml",
    "datetime": "2019-04-01 19:55:00",
    "code": "300630"
  },
  {
    "title": "普利制药2018年度净利润同比增长84% 拟10转5派2.1元",
    "href": "http://stock.jrj.com.cn/2019/04/01193927296251.shtml",
    "datetime": "2019-04-01 19:39:20",
    "code": "300630"
  },
  {
    "title": "普利制药：2018年净利同比增84% 拟10转5派2.1元",
    "href": "http://stock.jrj.com.cn/2019/04/01185727295788.shtml",
    "datetime": "2019-04-01 18:57:07",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用伏立康唑获得荷兰药物评价委员会（CBG）上市许可",
    "href": "http://stock.jrj.com.cn/2019/03/11201027148018.shtml",
    "datetime": "2019-03-11 20:10:53",
    "code": "300630"
  },
  {
    "title": "普利制药：股东综合制药减持公司1%股份",
    "href": "http://stock.jrj.com.cn/2019/03/04182627115851.shtml",
    "datetime": "2019-03-04 18:26:20",
    "code": "300630"
  },
  {
    "title": "普利制药：两家股东合计减持公司2.9858％股份",
    "href": "http://stock.jrj.com.cn/2019/02/28214127103325.shtml",
    "datetime": "2019-02-28 21:41:39",
    "code": "300630"
  },
  {
    "title": "普利制药：注射用伏立康唑拟纳入优先审评程序",
    "href": "http://stock.jrj.com.cn/2019/02/10174127025559.shtml",
    "datetime": "2019-02-10 17:41:00",
    "code": "300630"
  }
]